HORMONE SENSITIVE PROSTATE CANCER

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy and hormone therapy can better control advanced prostate cancer that has spread. It includes 60 men with a specific genetic feature or inflamed tumors. The goal is to see if this combination…

This early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in 142 men with a specific type of prostate cancer that shows up on a PSMA scan. The drug delivers a tiny dose of radiation directly to cancer cells. The main goals are to find the safest dose and to check …

This study tests whether adding the drug capivasertib to standard hormone therapy (abiraterone and ADT) can slow the growth of prostate cancer that has spread and has a specific genetic change (PTEN deficiency). About 1,000 men with this type of cancer will receive either the com…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk, nonmetastatic disease that worsened after initial treatment. About 1,068 men participated. The main goal was to see how long until…

This study looks at whether testosterone levels return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and side…

This study tracks how well treatment is working in men with metastatic hormone-sensitive prostate cancer using special PET scans (PSMA-PET). Twenty participants will get a scan before starting standard therapy and another after 6 months. The goal is to see if these scans can help…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…